Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.32 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.31 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CCR4 | P51679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2615681 | 0.94 | NPC1 (0.37) | NPC1CYP1A2RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL13168812 | 0.89 | CCR9 (0.36) | MLKLCCR4 | |
| SCHEMBL14582645 | 0.87 | ALDH1A1 (0.33) | NPC1CYP1A2RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL13044405 | 0.84 | NPC1 (0.38) | NPC1CYP1A2RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL13936700 | 0.83 | MLKL (0.33) | NPC1CYP1A2RAB9AMAPK1MLKL | |
| SCHEMBL10068049 | 0.83 | RXFP1 (0.36) | NPC1RAB9AALDH1A1SMN1; SMN2GAA | |
| SCHEMBL10067965 | 0.82 | MAPT (0.37) | ALDH1A1KMT2AKAT6A | |
| SCHEMBL3834184 | 0.82 | MLKL (0.33) | NPC1RAB9AALDH1A1KMT2AMLKL | |
| SCHEMBL2615674 | 0.82 | CCR9 (0.39) | SMN1; SMN2KMT2AMLKLCCR4 | |
| SCHEMBL3826176 | 0.82 | MLKL (0.35) | MLKL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096551-B2 | Method for producing 2-(triazinylcarbonyl) sulfonanilides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9096551-B2 | Method for producing 2-(triazinylcarbonyl) sulfonanilides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9096551-B2 | Method for producing 2-(triazinylcarbonyl) sulfonanilides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| EP-2655346-B1 | PROCESS FOR THE PREPARATION OF 2-(TRIAZINYLCARBONYL)SULFONANILIDES | BAYER IP GMBH (DE) | 2015-01-21 | — | — | EP | disclosed |
| EP-2655346-B1 | PROCESS FOR THE PREPARATION OF 2-(TRIAZINYLCARBONYL)SULFONANILIDES | BAYER IP GMBH (DE) | 2015-01-21 | — | — | EP | disclosed |
| US-20140024828-A1 | Method for producing 2-(triazinylcarbonyl) sulfonanilides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-23 | — | — | US | disclosed |
| US-20140024828-A1 | Method for producing 2-(triazinylcarbonyl) sulfonanilides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-23 | — | — | US | disclosed |
| US-20140024828-A1 | Method for producing 2-(triazinylcarbonyl) sulfonanilides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-23 | — | — | US | disclosed |
| EP-2655346-A2 | METHOD FOR PRODUCING 2-(TRIAZINYLCARBONYL) SULFONANILIDES | Bayer Intellectual Property GmbH (DE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012084857-A2 | METHOD FOR PRODUCING 2-(TRIAZINYLCARBONYL) SULFONANILIDES | BAYER CROPSCIENCE AG (DE) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012084857-A2 | METHOD FOR PRODUCING 2-(TRIAZINYLCARBONYL) SULFONANILIDES | BAYER CROPSCIENCE AG (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024828-A1 | Method for producing 2-(triazinylcarbonyl) sulfonanilides | AOX1, SULT1E1, CBR1 | NPC1 4480/4885CYP1A2 20/4885RAB9A 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.